Our partner is making history with every clinical advancement and aspires to turn hope into cures by unraveling new possibilities for genetic medicine. Almost 40 years ago, their scientific co-founder was the first to demonstrate that adeno-associated virus (AAV) could be cloned for therapeutic purposes. This groundbreaking research propelled the most exciting field in medical research today and inspires their world-leading gene therapy platform that is bringing new therapeutics to market and resulting in new methods for lowering the cost of delivery.

This critical hire joined an esteemed, world-renowned leadership team to continue to build upon a strong foundation and culture that values collaboration, patient care and innovation.